Eris Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 3.01 Cr
as on 31-10-2024
- Paid Up Capital ₹ 2.58 M
as on 31-10-2024
- Company Age 3 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 305.00 Cr
as on 31-10-2024
About Eris Therapeutics
The Company is engaged in the Machinery And Equipment Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.01 Cr and a paid-up capital of Rs 2.58 M.
The company currently has active open charges totaling ₹305.00 Cr.
Kaushal Shah, Inderjeet Negi, Sachin Shah, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230GJ2021PLC123519
- Company No.
123519
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
23 Jun 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Eris Therapeutics?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kaushal Shah  | Director | 23-Jun-2021 | Current |
| Inderjeet Negi | Director | 23-Jun-2021 | Current |
| Sachin Shah | Director | 23-Jun-2021 | Current |
| Nita Borkar | Additional Director | 10-Sep-2024 | Current |
Financial Performance and Corporate Structure Insights of Eris Therapeutics.
Eris Therapeutics Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Eris Therapeutics?
In 2023, Eris Therapeutics had a promoter holding of 99.94% and a public holding of 0.06%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Eris Bionxt Private LimitedActive 4 years 6 monthsKaushal Shah, Inderjeet Negi and 1 more are mutual person
Eris Lifesciences LimitedActive 17 years 10 monthsKaushal Shah and Inderjeet Negi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 15 Dec 2023 | ₹135.00 Cr | Open |
Citi Bank N.A. Creation Date: 08 Aug 2022 | ₹150.00 Cr | Open |
Citi Bank N.A. Creation Date: 08 Aug 2022 | ₹20.00 Cr | Open |
How Many Employees Work at Eris Therapeutics?
Eris Therapeutics has a workforce of 611 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eris Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eris Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
